Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 99.
8. lappuse
... means the Federal Food , Drug , and Cosmetic Act , as amended ( secs . 201-902 , 52 Stat . 1040 et seq . , as amended ; 21 U.S.C. 321-392 ) . ( b ) Department means the Department of Health and Human Services . ( c ) Secretary means the ...
... means the Federal Food , Drug , and Cosmetic Act , as amended ( secs . 201-902 , 52 Stat . 1040 et seq . , as amended ; 21 U.S.C. 321-392 ) . ( b ) Department means the Department of Health and Human Services . ( c ) Secretary means the ...
9. lappuse
... means the Secretary of Health and Human Services . ( d ) Commissioner means the Commis- sioner of Food and Drugs . ( e ) The term person includes individ- uals , partnerships , corporations , and associations . ( f ) The definitions and ...
... means the Secretary of Health and Human Services . ( d ) Commissioner means the Commis- sioner of Food and Drugs . ( e ) The term person includes individ- uals , partnerships , corporations , and associations . ( f ) The definitions and ...
23. lappuse
... means the Food and Drug Adminis- tration . ( 2 ) Adverse drug experience means any ad- verse event associated with the use of a drug in humans , whether or not considered drug related , including the following : an adverse event ...
... means the Food and Drug Adminis- tration . ( 2 ) Adverse drug experience means any ad- verse event associated with the use of a drug in humans , whether or not considered drug related , including the following : an adverse event ...
24. lappuse
... means an adverse drug experi- ence that is fatal or life - threatening , is per- manently disabling , requires inpatient hos- pitalization , or is a congenital anomaly , can- cer , or overdose . ( c ) Reporting requirements - 15 - day ...
... means an adverse drug experi- ence that is fatal or life - threatening , is per- manently disabling , requires inpatient hos- pitalization , or is a congenital anomaly , can- cer , or overdose . ( c ) Reporting requirements - 15 - day ...
26. lappuse
... mean absorption of at least 75 per- cent of the combined mean of the two reference standards is observed . Assist- ance in developing a 26 $ 310.500 21 CFR Ch . I ( 4-1-98 Edition )
... mean absorption of at least 75 per- cent of the combined mean of the two reference standards is observed . Assist- ance in developing a 26 $ 310.500 21 CFR Ch . I ( 4-1-98 Edition )
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning